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Abstract 
Cytomegalovirus (CMV) infection is increasingly recognized in critically ill immunocompetent patients. Some studies 
have demonstrated an association between CMV disease and increased mortality rates, prolonged intensive care unit 
and hospital length of stay, prolonged mechanical ventilation, and nosocomial infections. However, there is a consid‑
erable controversy whether such association represents a causal relationship between CMV disease and unfavorable 
outcomes or just a marker of the severity of the critical illness. Detection of CMV using polymerase chain reaction and 
CMV antigenemia is the standard diagnostic approach. CMV may have variety of clinical manifestations reflecting the 
involvement of different organ systems. Treatment of CMV in critical care is challenging due to diagnostic challenge 
and drug toxicity, and building predictive model for CMV disease in critical care setting would be promising to iden‑
tify patients at risk and starting prophylactic therapy. Our objective was to broadly review the current literature on the 
prevalence and incidence, clinical manifestations, potential limitations of different diagnostic modalities, prognosis, 
and therapeutic options of CMV disease in critically ill patients.
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Background
CMV disease is usually a disease acquired by adolescence 
and follows a benign course, while it might reactivate in 
patients with immune suppression and associated with 
high mortality and morbidity.
There is growing evidence that critically ill immuno-
competent patients can develop CMV disease. Studies 
have described CMV infection in immunocompetent sur-
gical, septic, burn, or trauma critically ill patients [1, 2]. 
Some studies have demonstrated an association between 
CMV disease and increased mortality rates, prolonged 
(ICU) and hospital length of stay, prolonged mechani-
cal ventilation, and increased rate of nosocomial infec-
tions [2, 3]. However, there is a considerable controversy 
whether such association represents a causal relation-
ship between CMV disease and unfavorable outcomes, 
or whether CMV disease only represents a marker for 
severe illness that carries poor clinical outcomes.
The objective of this review is to examine the up-to-
date literature regarding CMV disease in critically ill 
patients. We will review the studies that assessed preva-
lence and incidence of CMV disease refuting the differ-
ences among them leading to different results, clinical 
manifestations, pathogenesis, potential limitations of dif-
ferent diagnostic modalities, association with outcomes, 
and treatment options of CMV disease in critically ill 
patients.
Definitions
Primary CMV infection usually occurs during child-
hood and early adolescence and is usually asymptomatic 
or mild and self-limiting disease in immunocompetent 
patients. After the resolution of acute infection, CMV 
establishes latent phase mainly within leukocytes, namely 
mononuclear cells, and this stage is diagnosed with a 
positive anti-CMV IgG serology (seropositivity) and is 
characterized by maintenance of the viral genome in the 
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absence of production of lytic infectious virions but with 
the ability of the viral genome to reactivate under certain 
conditions [3].
CMV literature focused on immunocompromized 
population like transplant and AIDS populations; there-
fore, CMV disease statuses and definitions were based on 
that literature which defined CMV infection as detection 
of CMV genetic or molecular material in the patients’ 
serum or body fluids, indicating active replication of the 
virus. CMV infection according to that literature can 
occur as a result of reactivation of latent CMV or rein-
fection with an exogenous strain. Recurrent infection in 
immunocompromized patients is the detection of CMV 
genetic or molecular material in a patient who had pre-
vious documented infection and who has not had virus 
detected for an interval of at least 4 weeks during active 
surveillance [4]. Recurrent infection could be due to 
reactivation (if the detected strain is the same as the pri-
mary infecting strain) which is the most common mecha-
nism of acquiring the disease in adulthood, especially in 
immunocompromized population (seropositivity of the 
donor or recipient has been recognized as the most likely 
mechanism of acquiring the disease after organ trans-
plant; therefore, it is the recommended strategy for start-
ing CMV prophylactic treatment across most guidelines) 
[5–7], or new infection (different strains) [4]. Addition-
ally, de novo primary infection may occur in adults but is 
rare. However, the distinction between the three scenar-
ios, reactivation, new strain infection, and de novo pri-
mary infection, is difficult in practice, unless the patient 
is followed for a long time or the infecting source CMV 
genetic strains have been characterized.
CMV disease in critically ill adults will probably fall 
under one of these three mechanisms. Meta-analysis 
done by Osawa and Singh [8] has shown that CMV-
seronegative critically ill patients rarely developed CMV 
infection across most studies, suggesting that reactiva-
tion is the most likely mechanism of CMV disease in this 
population. However, the other two mechanisms may be 
responsible for the infection in some cases.
CMV end-organ disease has been defined as evidence 
of virus replication associated with clinical manifesta-
tions due to viremia or the invasion of organs such as the 
lungs, bone marrow, and colon [4].
The scope of this article is to examine CMV disease 
literature in critically ill overtly immunocompetent 
patients.
In summary, CMV is usually acquired in childhood, 
and the most common mechanism of the disease in 
adulthood is reactivation of latent virus whether in 
immunocompromized or critically ill population, fol-
lowed by rare incidence of recurrent new or de novo new 
infection.
Virus genome, pathogenesis, and virulence
CMV is the most common member of the herpes viruses 
to infect humans. Its double-stranded linear DNA duplex 
contains 165 genes that encode viral proteins that mimic 
and interact with human cellular proteins and are related 
to its virulence and latency.
CMV is maintained in a latent or low production state 
within monocytes mainly and dendritic cells (DC). They 
do not usually express viral genes in significant num-
ber due to the robust CD8+ cytotoxic T lymphocyte 
response and T memory cells. In immunocompetent 
individuals, asymptomatic viral shedding may be detect-
able in the saliva or urine; however, cell-mediated host 
immune responses prevent the development of overt 
CMV disease [3].
CMV genome is detected within early progenitor 
myeloid CD34+ cells, and monocytes and (DC) differ-
entiation will be the only lineage that will pass the CMV 
genome. Viral expression is closely related to expres-
sion of immediate early (IE) genes within monocytes 
and (DC), but expression of infectious (lytic) virions 
only happens within (DC), a process regulated by major 
IE enhancer promoter (MIEP) which is normally under 
repressors closely related to other factors and cytokines 
within the cells [3].
CMV disease occurs as a result of immunosuppres-
sion associated with critical illness. A landmark study by 
Clari showed that CMV infection in critically ill patients 
was consistently associated with undetectable IFN-γ T 
cell responses within the first 2 days of admission to the 
ICU, and that viral load was inversely related to IFN-γ T 
cell responses [9]. A study by Venet showed that septic 
patients display immune system paralysis, manifesting 
as reduced Th1 B cell function, increased IL-10 produc-
tion (anti-inflammatory), and global lymphopenia affect-
ing natural killer cells (NK) specifically quantitatively and 
most importantly qualitatively related to their interferon 
production, which is pivotal in attacking CMV-infected 
cells [10, 11]. CMV disease has also been linked to the 
cytokine storm associated with critical illness, specifi-
cally tumor necrosis factor alpha that activates nuclear 
factor κB, which enhances the replication of the dormant 
CMV DNA inside leukocytes, while enhancing the pro-
duction of cytokines and other proteins [12]. In animal 
models with bacterial sepsis, Toll-like receptor 4 signal-
ing and secreted inflammatory cytokines all have been 
found to be potential triggers for reactivation of latent 
CMV in immunocompetent mice lungs [13].
Under such critical conditions observed during sep-
sis, burns, trauma, or major surgery, the CMV genes 
are expressed and viral replication is initiated [14, 15], 
invading cells in the lung, kidney, liver, bone marrow, and 
intestine [3], and exerts direct cytotoxic effects.
Page 3 of 14Al‑Omari et al. Ann. Intensive Care  (2016) 6:110 
In addition, when CMV starts to replicate within leuko-
cytes, it has inherent escape mechanisms from the host 
immune system, and the CMV unique short (US 2, 3, 6, 
10, and 11) proteins down-regulate the surface expres-
sion levels of HLA-1 and HLA-2 on leukocytes that mark 
these cells to be attacked by CD8+ T lymphocytes [16].
Other CMV genes encode structural proteins, such as 
the matrix protein pp65, that is involved in down-regula-
tion of HLA-1 leukocytes surface markers and used as a 
target of antigen detection immune assays [17].
In addition, virulence is also related to boosting 
immune response causing more tissue damage, and this 
is due to homology of some of CMV proteins to inflam-
matory cytokines as human tumor necrosis factor alpha 
receptor and CXC chemokine such as interleukin-8 [18].
Animal model studies suggested that the outcome 
after reactivation might be determined by the viral load 
of the original infection, which correlates with the num-
ber of CMV-specific T memory cells, i.e., immunological 
responses (higher IgG levels), CD-8 cytotoxic cells, and 
hence inflated immune response during reactivation, and 
this might be a promising marker to predict the outcome 
in patients with reactivation [13, 19].
In addition, the virus has an immunosuppressive effect 
via its modulatory effect on cytokine production, which 
may enhance the susceptibility to secondary bacterial 
and fungal infections. CMV also has a direct suppressive 
effect on the bone marrow.
Some CMV proteins are also related to antiviral mech-
anisms, including the viral DNA polymerase UL54 and 
UL97, which encodes a protein phosphotransferase 
enzyme that phosphorylates the antiviral drug ganciclo-
vir, an essential activation step required for its inhibitory 
effect on CMV DNA replication [20–22].
In summary, CMV has a complicated genome that 
allows the virus to go into latent state and facilitate its 
evasion from immune response and homology to human 
chemokines, all of which is involved in its pathogenesis.
Risk factors
Several factors have been identified to be associated with 
CMV disease in critically ill patients (Table  1), includ-
ing requirement of mechanical ventilation on admission 
[8], an inflammatory status like sepsis [23–25]. Other 
reports have linked CMV disease to steroid use, but this 
finding has not yet been confirmed [26–28]. In addition, 
catecholamines surge associated with critical illness has 
been linked to CMV disease in myocardial infarction 
patients [25]. Several studies failed to show a correla-
tion between age and CMV infection [1, 24, 27, 29, 30], 
while the reported association with gender is inconsist-
ent across the literature [1, 2, 24, 27–29, 31]. Interest-
ingly, higher disease severity scores such as the acute 
physiology and chronic health evaluation (APACHE) II 
[1, 27, 29] and sepsis-related organ failure assessment 
(SOFA) [30] scores have not been found to be associated 
with increased risk of CMV disease. Active malignancy 
has not been shown to be a risk factor for CMV disease 
in critically ill patients [2, 24, 28].
Blood transfusion, especially in the first 24  h of criti-
cal illness, has been shown to be an important risk fac-
tor for CMV disease [1], which has been linked to the 
timing and the amount of blood transfused, although 
the mechanisms involved are unclear. Contamination 
of transfused blood with CMV-infected leukocytes may 
be responsible for some cases, especially in cases where 
the blood bank does not perform leukocyte depletion 
pre-transfusion [32, 33], even though leukocyte-depleted 
blood is not completely clear of leukocytes; hence, its use 
does not completely eliminate the risk of CMV infection. 
In addition, the immunomodulatory effect of transfusion 
may also predispose patients to CMV reactivation.
In summary, mechanical ventilation and blood transfu-
sion in the ICU have been associated with the develop-
ment of CMV disease, but no association with severity 
scores was found.
Epidemiology
Several epidemiologic studies assessed the incidence of 
CMV disease in critically ill patients (Table 2), and these 
studies used different methodologies that lead to varia-
tion in the observed incidence of infection ranging from 
0% to as high as 98%. This inconsistency in the results 
could be explained by many factors as variation in the 
definition of CMV disease (old studies considered sero-
positivity as evidence of CMV disease, while others used 
newer technologies as PCR and antigen detection), vari-
ation in inclusion criteria as some studies included only 
seropositive patients and hence assessed only reactiva-
tion rate of CMV rather than CMV infection rate which 
Table 1 Risk factors for CMV disease in critical care setting 
and their strength of association
Risk factor Strength of association
Immune compromised Strong association [49]
Age No evidence [8]
Gender Inconsistent data [8]
Mechanical ventilation Strong association [1, 8]
Sepsis Strong association [8, 47]
Corticosteroids use Weak evidence [27]
Blood transfusion Weak association [1, 27, 28]
Disease severity scores No association [1, 24, 27–31]
Active malignancy No association [2, 24, 28]
Stress (catecholamines surge) Weak association [25]
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might be slightly higher than reactivation by including 
seronegative patients developing new infection in addi-
tion to reactivation, all that in addition to variation in 
studied populations that ranged from all ICU patients to 
specific population such as septic, surgical, burn, or post-
cardiac surgery patients that might have different risks of 
CMV disease.
Variation in diagnostic methods used including select-
ing different specimens, some used serum, while others 
used urine, saliva, or bronchoalveolar lavage samples, 
tests were performed at different points in the ICU stay 
and testing time and frequency was not standardized in 
all studies as some left it up to the judgment of the treat-
ing team. Recent studies showed that CMV disease typi-
cally occurs within the first 2  weeks of critical illness. 
A study performed by Kalil and Florescu [34] showed 
that the diagnosis rate of CMV infection increased sig-
nificantly (from 1 to 21%) when patients who spent five 
or more days in the ICU were screened, pointing to a 
threshold in timing for the window to develop CMV in 
critical care setting. In a recent systematic review that 
included 13 studies (nine prospective and four retro-
spective), the incidence of CMV disease in critically ill 
patients, defined as the detection of antigenemia, DNAe-
mia, or positive viral culture from blood samples with or 
without other clinical specimens, ranged from 0 to 36%. 
Notably, the reported incidence of the disease was much 
higher in studies that screened the patients weekly than 
those that screened only once within the first 4  days of 
admission to the ICU (6–33 vs. 0.8–1.2%), indicating that 
the disease happens frequently beyond the first 4  days 
post-admission. Among the studies using PCR detection 
(which is the most sensitive diagnostic test for CMV), the 
mean and median times of detection ranged from 4 to 
12 days after ICU admission [8].
In summary, the incidence and demographics of CMV 
disease in the ICU were highly variable across studies, as 
a result of variation in study design and definition of the 
disease.
Clinical manifestations
Identification of CMV disease in immunocompetent 
patients is complicated by its non-specific symptoms, 
multiorgan involvement, and the fact that its clinical 
manifestations converge with those of the critical ill-
ness. Heininger et  al. [24] reported that serious organ 
involvement with CMV disease could occur in up to 
10% of cases. A systematic review of studies report-
ing the clinical manifestations of severe CMV disease 
in immunocompetent ICU patients found that the gas-
trointestinal tract (hepatitis, gastroenteritis, duodenitis, 
enteritis, colitis, proctitis) is to be the most common, fol-
lowed by central nervous system (encephalitis, myelitis, 
encephalomyelitis, meningitis, and meningioradicu-
lopathy), and hematological system (hemolytic anemia, 
thrombocytopenia, disseminated intravascular coagula-
tion, and pancytopenia) [35]. Other organs, such as the 
lungs and eyes, were rarely involved. CMV myocarditis, a 
recognized entity in immunocompromized patients, was 
not documented.
Vascular manifestations have been reported such as 
portal or femoropopliteal vascular thrombosis and pul-
monary embolism that is thought to be related to vascu-
lar endothelial cells damage [35].
The immunomodulatory effects of CMV may be 
responsible for increased risk of secondary bacterial and 
fungal infections in critical care setting [3, 4].
CMV pneumonia is a well-known clinical manifesta-
tion of CMV disease in immunocompromized patients. 
However, lung involvement may be less recognizable in 
immunocompetent critically ill patients especially if they 
were intubated for other reasons, but few studies dem-
onstrated that the prevalence of this disease in immuno-
competent critically ill patients may be as high as 50% 
in patients with ventilator-associated pneumonia or 
ICU-acquired acute respiratory distress syndrome [36]. 
However, CMV disease is not necessarily the pathologic 
cause of ICU-acquired pneumonia and discrimination 
between a causal or associative relationship is challeng-
ing because the diagnosis depends on quality of the res-
piratory sample, pathologist skills, and variation of the 
diagnostic test. As an example of this variation, Coi-
sel et  al. [37] studied patients mechanically ventilated 
who are seropositive for CMV and found significant 
increased mortality in CMV-positive group; in addition, 
the diagnostic yield of BAL CMV PCR was 73% in com-
parison with the detection of CMV antigenemia which 
was 46%. Heininger et  al. [38] studied patients admit-
ted with severe sepsis of whom 31% developed ICU-
acquired pneumonia and have shown slightly different 
diagnostic yield of tracheal aspirate CMV PCR of 70 ver-
sus 62% using blood CMV PCR. In a previous study, the 
same authors included only CMV surgical seropositive 
patients and found equal diagnostic yield between BAL 
PCR and blood PCR. Chiche showed different results, as 
the diagnostic yield of BAL was 26% (using CMV shell 
vial culture) compared to 85% using CMV antigenemia 
[26]. Papazian et al. [39] studied patients with ventilator-
associated pneumonia and made histologic diagnosis 
of CMV pneumonia in 29% of the patients. The study 
found that BAL shell vial culture had a sensitivity/speci-
ficity of 53, 92% in comparison with histologic diagnosis. 
Ong et al. [40] studied immunocompetent patients with 
ARDS and found a CMV reactivation incidence of 27%, 
which was associated with significant increase in ICU 
mortality.
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In general, CMV affects multiple organs at varying 
rates and severity. ICU-acquired pneumonia, especially 
VAP, appears to be a common CMV-associated disease 
that draw attention of ICU physicians and researchers.
Diagnosis
Critically ill patients have dynamic immune system that 
affects the CMV detection window. The fact that immune 
suppression is not expected usually on presentation to 
intensive care, coupled with the ability of infected indi-
viduals to control the disease and eventually clear the 
virus at some point, affects the accuracy of diagnostic 
methods for CMV, all of that in addition to the differ-
ential sensitivities and clinical utilities of the techniques 
used to detect CMV (Table 3). In one major study assess-
ing the rate of CMV disease in ICU patients, 50% of 
viremia was detected within the first 12  days of admis-
sion, but CMV infection was not detected earlier than 
the first 3 days [1].
Testing for CMV for the diagnosis of CMV disease 
should be based on predictors of CMV disease in addi-
tion to signs and other laboratory investigations directing 
toward viral origin of the current clinical status as indica-
tors of liver and gastrointestinal involvement [41].
Serology
The most commonly used tests to measure CMV-spe-
cific IgM or IgG levels are the enzyme-linked immune 
assays and anticomplement immunofluorescence 
assays. The presence of IgM antibodies indicates an 
acute CMV infection and can last for 4–6 months [42]. 
Because IgG seropositivity is long lasting, the measure-
ment of IgG antibodies is not a reliable method to diag-
nose CMV infection. Critically ill patients may develop 
immune paralysis (anergy) that limits their ability to 
mount immune responses; therefore, it is important 
to note that negative serology does not exclude CMV 
infection. The main utility of serology testing at present 
is to screen for the potential of latent CMV reactivation 
[42].
PCR
Due to its high sensitivity and rapid turnaround time, 
PCR is considered the gold standard method of diagnos-
ing CMV infection [8]. Both qualitative and quantitative 
(viral load) PCR assays are available. However, quantita-
tive tests are preferred as it quantifies viral load, which 
has prognostic importance [1]. Whole blood testing is 
more sensitive than plasma testing because it enables the 
detection of cell-free and intracellular viruses [43].
CMV antigen assays
Antigen assays using immunofluorescent antibodies are 
quick and easy to perform and can be used to detect the 
CMV pp65 antigen in leukocytes [4]. In one study that 
compared PCR to antigen detection to diagnose CMV 
infection in critically ill patients, the antigen detection 
method was unable to identify 5 of the 11 CMV-posi-
tive patients detected by PCR. In addition, the diagnos-
tic time of the PCR method was ahead than that of the 
antigen detection method [29]. However, meta-analyses 
performed by Osawa and Kalil revealed that the sensi-
tivities and specificities of antigen detection methods 
are comparable to those of PCR detection methods [8, 
44]. The only potential limitation of antigen assays is 
their low sensitivity in patients with leukopenia [5].
Viral culture
Culture-based assays are not clinically used due to their 
low sensitivity and delay in receiving the results [8]. In a 
meta-analysis by Osawa and Singh [8], detection rate of 
CMV infection among studies using culture was 0–20% 
of CMV infections, whereas it was 0–32% using PCR 
and antigen assays. In a meta-analysis performed by Kalil 
and Florescu [34], the PCR/antigen detection methods 
achieved a CMV detection rate of 20%, whereas that the 
culture method was only 12%.
Histopathology
Histopathology is the most specific method for diag-
nosing CMV, especially by detecting organ-specific 
Table 3 Diagnostic methods of CMV, advantages, and disadvantages
Diagnostic method Advantages Disadvantages
Anti‑CMV immunoglobulins Might be used for screening for latent CMV infection Low sensitivity and specificity for active infection
CMV PCR assays High sensitivity and specificity and considered gold stand‑
ard, quick easy to perform, gives information of viral load, 
can be used for wide variety of samples
Better to be performed on whole blood, qualitative 
might be so sensitive and detect “innocent viral 
shedding” quantitative might be superior
CMV antigen assays Quick and easy to perform, has comparable sensitivity and 
specificity to PCR
Might be inferior to PCR in case of leukopenia
Viral culture Highly specific, can be performed on wide variety of 
samples
Time‑consuming, low sensitivity
Histopathology Highly specific, confirm CMV disease and pathogenicity  
and invasiveness
Invasive, low sensitivity, liable to sampling error, needs 
skilled pathologist and so operator dependent
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manifestations related to CMV. However, this method is 
invasive and has a limited sensitivity that depends on the 
sampling site and pathologist’s skills.
We suggest using CMV PCR or CMV antigen detection 
assays to diagnose CMV disease not earlier than 3  days 
and up to 2 weeks after the onset of critical illness, espe-
cially when the pretest probability of the disease is high 
[1, 8].
Prognosis
Studies addressing association of CMV disease and 
outcome in critically ill patients revealed inconsistent 
results.
A systematic review by Osawa and Singh [8] concluded 
that CMV disease in critically ill patients was associ-
ated with hepatic, respiratory, and renal dysfunctions; 
prolonged ICU stay, prolonged mechanical ventilation, 
increased incidence of bacterial and fungal infections, 
and increased mortality.
In a landmark prospective cohort study by Limaye 
et  al. [1] of 120 CMV-seropositive critically ill patients, 
he found significant association between CMV disease 
and 30-day mortality and increased ICU length of stay. 
Notably high levels of viremia were associated with 
increased mortality and morbidity rates, as well as pro-
longed lengths of stay in the hospital, the latter of which 
increased with each log increase in the number of CMV 
copies (>1000 copies/ml up to 28 days of hospital length 
of stay). In addition, he observed higher rate of hospi-
talization beyond 30 days in CMV-infected patients indi-
cating a long-term effect of CMV disease that persists 
beyond ICU discharge and even after clearance of the 
viremia. Of note, the study could not identify a relation-
ship between the severity of critical illness (APACHE) 
and the risk of CMV disease, probably refuting the idea 
that CMV disease might be a marker of the underlying 
disease severity.
Regarding specific ICU population, a recent observa-
tional prospective study that included 86 CMV-seropos-
itive septic patients found an association between CMV 
disease and longer ICU stay, prolonged mechanical venti-
lation, and impaired pulmonary gas exchange [38]. Coisel 
examined critically ill patients with ventilator-associated 
pneumonia and found a significant increase in ICU and 
60-day mortality (50% CMV group vs. 20% in control 
group), longer ICU stay, and less ventilator-free days in 
patient with CMV disease [37].
On the other hand, a prospective observational study 
of 80 mechanically ventilated patients that were seroposi-
tive for CMV found no association between CMV dis-
ease and 28-day mortality, ICU mortality, ICU length of 
stay, or duration of mechanical ventilation, although the 
SOFA score was significantly higher in CMV-infected 
group [12]. Similar findings were also reported in a study 
that used CMV pp65 antigenemia as evidence of CMV 
disease [28].
These inconsistent findings are probably related to dif-
ferences of studied populations, retrospective nature 
of several studies, differences in diagnostic tests, the 
unmeasured confounders; therefore, it is difficult to 
establish proved causality based on the existing studies, 
necessitating future studies with strict methodology in 
relation to blinding, studied population, testing timing, 
and method of testing preferably with tissue studies to 
clarify the causal relation between CMV disease and ICU 
mortality and morbidity.
In conclusion, although the current literature is incon-
sistent, there is strong evidence suggesting an association 
between CMV disease and higher morbidity and mortal-
ity in the ICU.
Treatment and prevention
The central controversy of CMV disease in critically ill 
patients is whether to treat or not and whether treatment 
makes a difference to the patient’s outcomes or not.
Treatment of CMV disease as any other disease should 
be based on a benefit/risk ratio, taking into considera-
tion all other factors associated with the diagnostic pro-
cess and treatment such as invasiveness of the diagnostic 
method, side effects of anti-CMV medications which 
might be serious especially in critical ill patients, and risk 
of emergence of CMV resistance to the medications [45]. 
There is an agreement regarding treatment of established 
CMV disease and prophylactic treatment for certain pop-
ulations of immunocompromized patients as is the case 
in organ transplant recipients, for whom the guidelines 
are well established [7, 44].
Similarly, the curative treatment of clinically confirmed 
CMV disease (detection of significant CMV viral load by 
PCR or antigen detection based on diagnostic method 
threshold, in addition to clinical condition attributed to 
CMV and ruling out other potential causes) in immuno-
competent critically ill patients has been recommended, 
and support for such approach comes from studies like 
the one by Eddleston et  al. [46] that examined the out-
come of previously reported 34 cases of severe CMV 
disease in immunocompetent patients. It was found that 
multiorgan involvement was associated with poor out-
come compared with isolated central nervous system 
involvement. Among patients with multiorgan involve-
ment, 5 of 6 patients who received treatment of either 
ganciclovir or foscarnet recovered, while only 4 of 18 
patients who did not receive either one of the above-
mentioned drugs survived. The outcome noticed in this 
review pointed toward a potential benefit of antiviral 
treatment in this group of patients.
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However, the benefit of preemptive treatment of sub-
clinical detected viral replication with no proven direct 
organ pathology attributed to CMV, and the prophylac-
tic treatment in immunocompetent patients deemed to 
be at risk of developing CMV disease is much less clear 
[45]. It is plausible to assume that the best strategy to 
handle CMV disease in the ICU is to prevent reactivation 
in seropositive patients as these are at high risk of devel-
oping the disease. At present randomized clinical trials 
examining the safety and efficacy of preventative strate-
gies in critically ill patients are still going on.
Challenges for CMV preemptive and prophylactic 
treatment includes discouraging safety profiles of anti-
CMV medications on the kidney and bone marrow espe-
cially in critically ill patients who already have organ 
dysfunction that puts them at extra risk of further dys-
functions and secondary infections (Table 4).
The other challenge is the detection of CMV, the cur-
rent used methods, namely CMV PCR and CMV anti-
genemia, are highly accurate regarding sensitivity and 
specificity, but the challenge is that detection of CMV 
is highly sensitive to the timing and frequency of test-
ing which is related to the window of emergence of CMV 
infection within the first 2 weeks of critical illness but not 
earlier than 3 days [8, 44]; secondly, it is unclear whether 
some cases represent innocent viral DNA or antigen 
shedding not necessarily related to tissue invasiveness 
and thus does not require therapy, which stress against 
random screening for CMV [13].
Papazian recommended in his recent review that treat-
ment for evident CMV replication (blood or BAL signifi-
cant viral load or antigen titer) is not indicated unless it 
is associated with lung infiltrates and at least two fac-
tors (prolonged mechanical ventilation, absence of bac-
terial agent, leukopenia, hemophagocytosis, high liver 
enzymes, hyperbilirubinemia, fever, or diarrhea) which if 
found points for CMV being a pathogen invading multiple 
organs and not only a bystander or innocent viral shed-
ding [41].
So far no definite criterion is available to guide which 
critically ill patients should be screened for CMV disease. 
According to available literature certain populations as 
septic, burns, trauma, ICU-acquired pneumonia espe-
cially mechanically ventilated patients have been found 
at high risk of developing CMV disease across multiple 
studies [26, 41, 47]. Many authors recommended in these 
populations especially in case of prolonged mechanical 
ventilation with evidence of pneumonia, unexplained 
liver derangement or fever or unexplained digestive 
tract pathology, to screen for CMV disease and in case 
of CMV detection using PCR or antigenemia detection 
methods; then, treatment should be taken as benefit/risk 
ratio [37, 41, 48] (Table 4).
Regarding preemptive treatment, immunological assess-
ment of IFN-γ produced by CMV-specific CD8+ T cells 
and NK cell function as mentioned in virulence section 
might be a strong trigger to start preemptive treatment 
for detected CMV, because there is evidence that impaired 
CMV-specific CD8+ T cells IFN-γ production prior to 
CMV reactivation predicts poor outcome, which favors 
treatment. This has not been applied clinically so far but 
might be promising in the future for challenging cases [10].
CMV might acquire resistance to the limited number of 
medications that are currently available; hence, their pro-
phylactic use should be confined to confirmed cases or 
preemptive treatment until clear risk assessment tools for 
prophylactic therapy are developed in high-risk groups in 
the ICU [48].
Conclusion
There are many uncertainties about CMV disease in the 
critically ill patients. First, while identification of the 
virus is common in critically ill patients, the actual rate 
of CMV as a disease in critically ill patients is unclear. 
Second, the importance of CMV detection in critically ill 
patients remains questionable, especially in the absence 
of histologic evidence of infection. On the other hand, 
the existing evidence is strong regarding the association 
Table 4 Anti-CMV medications and common associated side effects
Agent Mechanism of action Common side effects
Ganciclovir Competitively inhibits the binding of deoxyguanosine triphos‑
phate to DNA polymerase resulting in inhibition of viral DNA 
synthesis
Thrombocytopenia, leukopenia, increased creatinine, 
fever, vomiting, diarrhea
Valganciclovir Converted to ganciclovir in the body, much higher bioavailability 
of ganciclovir compared to oral ganciclovir
As ganciclovir
Foscarnet Non‑competitive inhibitor of many viral RNA and DNA polymer‑
ases
Electrolyte abnormalities, fever, vomiting, diarrhea, 
anemia, granulocytopenia, renal insufficiency, car‑
diotoxicity, central nervous system toxicity, hepatic 
toxicity
Cidofovir Suppresses CMV replication by selective inhibition of viral DNA 
synthesis
Fever, alopecia, rash, ocular, renal, and gastrointestinal 
toxicity, cough, dyspnea
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between CMV detection and increased mortality and 
morbidity rates in ICU settings.
Still there are no high-quality data to guide the deci-
sion regarding when to treat detected CMV in ICU 
patients if there is no definite clinical confirmation of 
CMV disease (preemptive treatment), and there is no 
risk assessment tool to guide prophylactic therapy in 
ICU setting.
There is a need for well-conducted studies to develop 
risk assessment tool of CMV disease in critically ill 
patients, to estimate the real burden of CMV disease, 
and to examine the effect of prophylactic and preemp-
tive treatment on morbidity and mortality. Potential 
answers to these questions will hopefully be answered 
by currently ongoing trials related to CMV in critical 
care. “Cytomegalovirus Control in Critical Care trial” 
(NCT01503918) is addressing the safety and success 
rate regarding preventing reactivation of latent cyto-
megalovirus infection in critically ill patients when 
treated with one of two different antiviral regimens: 
“Valaciclovir/Aciclovir or not.” “Study of Ganciclo-
vir/Valganciclovir for Prevention of Cytomegalovirus 
Reactivation in Acute Injury of the Lung and Respira-
tory Failure” (NCT01335932) is addressing whether 
administration of ganciclovir in CMV-seropositive 
patients reduces serum IL-6 levels in immunocompe-
tent adults with severe sepsis or trauma-associated res-
piratory failure based on the hypothesis that pulmonary 
and systemic CMV reactivation amplifies both lung 
and systemic inflammation mediated through specific 
cytokines. “Preemptive Treatment of Herpesviridae 
trial” (NCT02152358) is addressing whether preemptive 
treatment by ganciclovir (for positive CMV viremia) or 
aciclovir (for positive HSV oropharyngeal PCR) is able 
to increase the number of ventilator-free days at day 60 
in ICU patients with prolonged mechanical ventilation 
having evident viral replication.
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